AB2 Bio

Focus: AB2 Bio is a Swiss diagnostics company headquartered in Lausanne focused on oncology applications. Company scale and maturity details are not publicly available.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About AB2 Bio

AI assessmentNot Hiring

No open roles listed right now. Follow AB2 Bio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Tadekinig alfa

NLRC4-MAS

Phase 3

Clinical Trials (3)

NCT03512314Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension

Phase 3

Help build intelligence for AB2 Bio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline includes Phase 3 program (Tadekinig alfa) for rare NLRC4-MAS with 3 active trials, offering exposure to late-stage development
Swiss headquarters in Lausanne provides access to strong biotech ecosystem and international scientific community
Focused oncology/diagnostics strategy suggests concentrated R&D mission with clear scientific direction

Watch Out For

No active job openings currently listed, limiting near-term hiring opportunities
Limited publicly available financial data, funding history, and employee count raises transparency and stability questions
Pre-revenue stage with minimal publication output (0 recorded) suggests early-stage execution risk and limited commercial validation

Generated by Claude from AB2 Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT03113760Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

Phase 3

NCT02398435Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo